CY1126128T1 - Εξατομικευμενα εμβολια για τον καρκινο - Google Patents

Εξατομικευμενα εμβολια για τον καρκινο

Info

Publication number
CY1126128T1
CY1126128T1 CY20231100248T CY231100248T CY1126128T1 CY 1126128 T1 CY1126128 T1 CY 1126128T1 CY 20231100248 T CY20231100248 T CY 20231100248T CY 231100248 T CY231100248 T CY 231100248T CY 1126128 T1 CY1126128 T1 CY 1126128T1
Authority
CY
Cyprus
Prior art keywords
cancer
tumor
patient
relates
present
Prior art date
Application number
CY20231100248T
Other languages
English (en)
Inventor
Ugur Sahin
Sebastian Kreiter
Mustafa DIKEN
Jan DIEKMANN
Michael Koslowski
Cedrik Britten
John Castle
Martin LÖWER
Bernhard RENARD
Tana Omokoko
Johannes Hendrikus DE GRAAF
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50185364&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126128(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CY1126128T1 publication Critical patent/CY1126128T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Computation (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)

Abstract

Η παρούσα εφεύρεση αφορά την παροχή εμβολίων, τα οποία είναι ειδικά για τον όγκο ενός ασθενούς και είναι δυνητικά χρήσιμα για την ανοσοθεραπεία του πρωτογενούς όγκου, καθώς και των μεταστάσεων του όγκου. Σε μια πτυχή, η παρούσα εφεύρεση αφορά μια μέθοδο για την παροχή ενός εξατομικευμένου εμβολίου κατά του καρκίνου, η οποία περιλαμβάνει τα εξής βήματα: (α) προσδιορισμό ειδικών για τον καρκίνο σωματικών μεταλλάξεων σε δείγμα όγκου ενός ασθενούς με καρκίνο για την παροχή υπογραφής μεταλλάξεων καρκίνου του ασθενούς και (β) παροχή εμβολίου που χαρακτηρίζει την υπογραφή μεταλλάξεων καρκίνου που λαμβάνεται στο βήμα (α). Σε μια άλλη πτυχή, η παρούσα εφεύρεση αφορά εμβόλια, τα οποία μπορούν να ληφθούν με την εν λόγω μέθοδο.
CY20231100248T 2011-05-24 2023-05-25 Εξατομικευμενα εμβολια για τον καρκινο CY1126128T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP12723117.3A EP2714071B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
EP21168360.2A EP3892295B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
CY1126128T1 true CY1126128T1 (el) 2023-11-15

Family

ID=50185364

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20191100986T CY1122110T1 (el) 2011-05-24 2019-09-18 Εξατομικευμενα εμβολια για τον καρκινο
CY20211100945T CY1124685T1 (el) 2011-05-24 2021-11-02 Εξατομικευμενα εμβολια για τον καρκινο
CY20231100248T CY1126128T1 (el) 2011-05-24 2023-05-25 Εξατομικευμενα εμβολια για τον καρκινο

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20191100986T CY1122110T1 (el) 2011-05-24 2019-09-18 Εξατομικευμενα εμβολια για τον καρκινο
CY20211100945T CY1124685T1 (el) 2011-05-24 2021-11-02 Εξατομικευμενα εμβολια για τον καρκινο

Country Status (8)

Country Link
EP (4) EP4223311A1 (el)
CY (3) CY1122110T1 (el)
DK (1) DK3473267T3 (el)
HR (1) HRP20191535T1 (el)
ME (1) ME03498B (el)
PL (2) PL2714071T3 (el)
RS (1) RS59369B1 (el)
SI (1) SI2714071T1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2714071T3 (pl) 2011-05-24 2019-12-31 Biontech Rna Pharmaceuticals Gmbh Zindywidualizowane szczepionki przeciwrakowe
HUE057608T2 (hu) 2011-05-24 2022-06-28 BioNTech SE Individualizált vakcinák a rák ellen
JP7477888B2 (ja) * 2018-11-15 2024-05-02 ノイスコム アーゲー 個別化された癌ワクチンの作製のための癌変異の選択

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU1774299A (en) 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
ES2344078T3 (es) 2001-06-05 2010-08-17 Curevac Gmbh Arnm estabilizado con un contenido de g/c aumentado para la terapia genetica.
US20060204523A1 (en) * 2001-11-26 2006-09-14 Khromykh Alexander A Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
PL2714071T3 (pl) 2011-05-24 2019-12-31 Biontech Rna Pharmaceuticals Gmbh Zindywidualizowane szczepionki przeciwrakowe

Also Published As

Publication number Publication date
DK3473267T3 (da) 2021-10-18
EP2714071A2 (en) 2014-04-09
EP3892295B1 (en) 2023-04-26
ME03498B (me) 2020-04-20
SI2714071T1 (sl) 2019-11-29
EP3473267B1 (en) 2021-09-08
EP2714071B1 (en) 2019-07-10
CY1122110T1 (el) 2020-11-25
CY1124685T1 (el) 2022-07-22
HRP20191535T1 (hr) 2019-11-29
EP3892295A1 (en) 2021-10-13
PL2714071T3 (pl) 2019-12-31
EP3473267A1 (en) 2019-04-24
RS59369B1 (sr) 2019-11-29
EP4223311A1 (en) 2023-08-09
PL3473267T3 (pl) 2022-01-10

Similar Documents

Publication Publication Date Title
CY1126128T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
BR112013029834A8 (pt) vacinas individualizadas para câncer
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
CY1124279T1 (el) Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1122005T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1126300T1 (el) Bcma (cd269/tnfrsf17) - πρωτεϊνες δεσμευσης
CY1122754T1 (el) Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
BR112018012374A2 (pt) identificação, fabricação e uso de neoantígeno
CY1122453T1 (el) Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
BR112017020893A2 (pt) método para o tratamento de câncer
CY1125338T1 (el) Λιποκατιονικα δενδριμερη και χρησεις εξ αυτων
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων